Our Results

SPL026 Phase I Healthy Volunteer Study

We completed a Phase I study in healthy volunteers as part of the combined Phase I/IIa clinical trial of SPL026 with supportive therapy for the treatment of Major Depressive Disorder. The study, which was conducted at Hammersmith Medicines Research in collaboration with Imperial College London, was a dose-escalating, placebo-controlled Phase I study in 32 healthy psychedelic-naïve volunteers across four cohorts who received either SPL026 (n=24) or placebo (n=8) with supportive therapy.

The study demonstrated that intravenous (IV) administration of SPL026 offers a short-lived, well-tolerated psychedelic experience of ~20 minutes. In the three-month study period, no serious adverse events were reported and minimal mild, short-lived adverse events that were resolved spontaneously on dosing day.

The results of the study were presented at the European College of Neuropsychopharmacology (ECNP) Congress in October, 2022. A poster presentation was also delivered at the CNS Summit in November, 2022. 

Small Pharma talks

According to the Royal College of Psychiatry, mental illness is likely to be the second pandemic.

Watch our Chief Medical and Scientific Officer, Dr Carol Routledge, chat with Alastair Campbell as they discuss depression, DMT-assisted therapy and the future of treatments for mental health.

About Small Pharma

We’re a biotechnology company researching and developing short-acting psychedelics with supportive therapy for mental health conditions.

Register for Company Updates


    Corporate Presentation

    Follow us: